||
Minderbroedersstraat 10, B-3000 Leuven, Belgium.
Table of contents graphic.
Abstract. Fosmidomycin is the first representative of a new class of antimalarial drugs acting through inhibition of 1-deoxy-D-xylulose 5-phosphate (DOXP) reductoisomerase (DXR), an essential enzyme in the non-mevalonate pathway for the synthesis of isoprenoids. This work describes a divergent strategy for the synthesis of a series of -aryl substituted fosmidomycin analogues, featuring a palladium-catalyzed Stille coupling as the key step. An -(4-cyanophenyl)fosmidomycin analogue emerged as the most potent analogue in the present series. Its antimalarial activity clearly surpasses that of the reference compound fosmidomycin.
Introduction. According to the WHO, malaria still causes 1.5 to 2 million casualties in Africa alone, amongst which mainly children. One of the major reasons for the spreading of the disease is the growing resistance of Plasmodium falciparum, the parasite species responsible for the most of the diagnosed cases, towards almost every antimalarial drug currently available. Therefore, the discovery of novel inhibitors targeting new biochemical pathways is of high priority.
In 1980, Okuhura and colleagues reported the first isolation of fosmidomycin (1), a structurally simple antibiotic from Streptomyces lavendulae.
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In 1998, 1-deoxy-D-xylulose 5-phosphate (DOXP) reductoisomerase, an enzyme involved in the 2C-methyl-D-erythritol 4-phosphate (MEP) pathway for the biosynthesis of isoprenoids and absent in humans, was identified as the molecular target for fosmidomycin. 3, 4 Fosmidomycin was found to be a potent inhibitor of DOXP reductoisomerase (DXR) of P. falciparum. 4 FR900098 (2), the acetyl congener of fosmidomycin, was shown to be approximately twice as active against P. falciparum in vitro, as well as in a P. vinckei mouse model. 4 Due to this promising antimalarial activity, fosmidomycin received considerable attention, and recent clinical trials conducted in Gabon and Thailand confirmed the potential of fosmidomycin as an antimalarial drug. 5, 6 These important discoveries stimulated research on the chemical synthesis of fosmidomycin analogues. Structural changes of fosmidomycin and FR900098 could provide essential information on the structure-activity relationship and produce improved leads for the treatment of malaria. Mostly, attention was focused on the modification of the phosphonate and hydroxamate moieties, yielding, on one hand, various phosphonate prodrugs aimed to enhance the oral bioavailability, and on the other hand, modifications of the retrohydroxamate moiety into a hydroxamic acid, amongst others. [7] [8] [9] [10] [11] Structural variations of the three-carbon spacer, however, are scarce. Our group recently reported the synthesis of conformationally restricted analogues in which the carbon spacer was part of a cyclopropyl or cyclopentyl ring. 12, 13 Up to date, the most promising modifications of the carbon spacer consist of the introduction of an aryl substituent in α-position of fosmidomycin or FR900098. 14 Recently, we identified the α-3,4-dichlorophenyl substituted fosmidomycin analogue which exhibits a 12 times stronger in vitro antimalarial activity (Dd2 and 3D7 strains of P. falciparum) compared to fosmidomycin. Lately, Kurz and coworkers evaluated the effect of α-substituents on pivaloyloxymethyl ester prodrugs of fosmidomycin and FR900098. 15, 16 The α-methyl and phenyl analogues proved almost equipotent and the 3,4-difluorophenyl analogue slightly better than the FR900098 prodrug in inhibiting growth of a 3D7 P. falciparum strain. 15 Incorporation of an arylmethyl moiety in -position generally resulted in a marked decrease in activity. 16 Unfortunately, the strategy used to synthesize the α-aryl substituted analogues involved a de novo synthetic approach, which permitted only to synthesize a limited number of examples. To further explore the structure-activity relationship of this class, a strategy involving the incorporation of the aryl moiety at a later stage in the synthesis would be desirable.
Results and discussion. Here we describe a highly efficient divergent synthesis of a series of 18, 19 introduction of a protected hydroxylamine moiety only succeeded using N-benzyloxy-2-nitrobenzenesulfonamide. 20 Indeed, the 2-nitrobenzenesulfonamide (or nosyl/Ns) moiety effectively enhances the acidity of the proton on the nitrogen, whereas in the case of the Boc-protected hydroxylamine, its acidity is not sufficient for reaction to occur.
Subsequently, a palladium(0)-catalyzed addition of Bu 3 SnH to the triple bond of compound 9 afforded 1-tributylstannyl-propenylphosphonate 6 as a single isomer in an excellent yield of 90%. The E-geometry was assigned based on the 3 J PH coupling constant in the 1 H NMR spectrum (62.7 Hz), which is in accordance with the large coupling constant typically found for a vinylic proton trans to a phosphonate. 21 Optimization of the Stille coupling on the organotin derivative 6 afforded compounds 10f-g in good yields using a combination of Pd 2 dba 3 .CHCl 3 , tri(2-furyl)phosphine and anhydrous CuI in NMP. 22 Under these conditions, apparently no homo-coupling of 6 was detected and the geometry of the double bond was retained. Removal of the nosyl group of 10f-g with thiophenol and K 2 CO 3 followed by in situ acylation, however, provided compounds 12f-g in rather disappointing yields. 23 Apparently, the specific conditions used for the deprotection of the nosyl group are not fully compatible with the (substituents on the) aryl moiety. Therefore, we investigated if steps d and e could be
interchanged. An additional advantage of moving the nosyl deprotection step forward in the synthesis is that it enhances the divergent character of the sequence. Thus, compound 6 was first deprotected and in situ acylated in excellent yield. Subsequent Stille coupling on the organotin compound 11 using the above-mentioned conditions led to compounds 12a-h in good to excellent yields. The method proves highly compatible with a wide range of diverse functionalities, including hetereoaromatic rings (12g-h). The current methodology requires the use of aryl iodides, since aryl bromides only induced homo-coupling of 6. 4-Iodobenzamide, required for preparing 12c, is not commercially available, but was readily synthesized from 4-iodobenzonitrile.
Reduction of the ,-double bond, combined with removal of the benzyl protecting group on compounds 12a-f, was accomplished using palladium on carbon (10% Pd/C) and anhydrous Na 2 CO 3 in dry THF under slightly positive atmospheric H 2 -pressure. Reaction times varied from 3 to 14 h to afford compounds 13a-d,i-j in moderate to excellent yields. During this hydrogenation step little or no deoxygenation of the hydroxamic acid was observed, in contrast to previously reported N-O bond cleavage during catalytic hydrogenation. 13 In case of the conversion of compound 12b, short reaction times were necessary to prevent reduction of the nitrile substituent on the phenyl ring. Reduction of the nitro group in compounds 12e-f was unavoidable, resulting in amino-compounds 13i-j. Furthermore, reduction of the 2-thienyl (12g) and 3-thienyl (12h) compounds was successfully accomplished only when using more than 1 equivalent of Pd/C. Presumably the sulphur atom in the thiophene ring is poisoning the catalyst. Remarkably, simultaneous removal of the benzyl protecting group was not observed for these thienyl compounds, yielding the O-protected saturated compounds 14g-h.
Subsequent deprotection of the benzyl protecting group with BCl 3 afforded compounds 13g-h in good to excellent yields. Finally, the phosphonate ester groups of the -aryl FR900098 analogues 13a-d,g-j were cleaved with TMSBr. Two different methods for purification of the final phosphonic acid compounds were used. The first, more traditional method involves removal of the solvent, addition of water, lyophilisation of the solution and purification of the solids via reversed phase chromatography. This method was used for the purification of compounds 3a,d,i-j but suffers from some serious drawbacks. First, the resulting phosphonic acids are only sparingly soluble in water or MeOH. Second, the C-18 reversed phase column used for purification strongly absorbs the phosphonic acids 3a,d,i-j, resulting in a low recovery. This pronounced retention was not observed for more polar fosmidomycin analogues, 12 hence it could be correlated to the affinity of the aryl moiety for the stationary phase of the HPLC column. Third, the C-18 HPLC column used only allows for a maximum loading of 30 mg of crude material each time, which is very time consuming for the purification of larger amounts of crude analogues. Therefore, a second methodology was investigated, comprising removal of the solvent, addition of water followed by dropwise addition of a 5% aqueous NH 4 OH solution until pH 8-9 was reached. Subsequently, the solution was lyophilised and the product was purified via column chromatography using Whatman CF11-cellulose. 24 LC-MS analysis of the crude solids before chromatographic purification only showed NH 4 Br (resulting from a reaction of TMSBr with NH 4 OH) as a contaminant. The CF11-cellulose proved very effective in separating this contaminant from compounds 4b-c,g-h, which were isolated in high yields due to the low affinity for the stationary phase. Additionally the resulting bis-ammonium salts of the α-aryl phosphonates showed excellent solubility in water. Because of the difficulties associated with the handling of P. falciparum DXR, we investigated the ability of the synthesized -aryl substituted FR900098 analogues 3a,d,i-j and 4b-c,g-h to inhibit the highly homologous recombinant E. coli DXR. The conversion of DOXP to MEP by the enzyme was determined in an assay based on the NADPH dependency of the reaction. 25 With respect to the slow, tight-binding properties of fosmidomycin and probably most of its derivatives the inhibitors were pre-incubated with the enzyme and NADPH before the reaction was started by the addition of DOXP. 7, 11, 26 The results are summarized in Table 1 In previous studies, the -aryl substituted N-formyl-fosmidomycin analogues were generally superior DXR inhibitors as compared to their N-acetyl counterparts. Hence, we decided to synthesize the N-formyl congener of 4b, the most potent N-acetyl analogue in the present study. Towards the synthesis of 5 the above-mentioned strategy proved equally useful upon substituting in situ N-acetylation for N-formylation, using a mixture of HCOOH and 1,1'-carbonyldiimidazole.
(Scheme 2)
In the enzyme assay (Table 1) , compound 5 was approximately twofold more active than its acetyl congener 4b and equally active to fosmidomycin (1). More importantly, an in vitro antimalarial assay using intraerythrocytic stages of the P. falciparum D2d strain, proved that the activities of 4b (IC 50 = 0.27 M) and 5 (IC 50 = 0.27 M) surpass the activity of fosmidomycin (IC 50 = 1.1 M) and even FR900098 (IC 50 = 0.49 M) to inhibit parasite growth.
In conclusion, a highly accessible, divergent procedure for the preparation of α-arylsubstituted fosmidomycin analogues 3, 4 and 5 with varying substituents was developed using a palladium(0)-catalyzed Stille coupling as a key step. The required organotin precursor 6 was prepared regio-and stereoselectively in four steps from protected propargyl alcohol 7, using a Pd(0)-catalyzed addition of tributyltin hydride as a key step. Two compounds (4b and 5), both possessing an -4-cyanophenyl group, exhibited a promising in vitro inhibitory activity for recombinant E. coli DXR comparable to that of fosmidomycin, and were even found to show a higher activity than fosmidomycin in an in vitro test against P. falciparum D2d strain.
Experimental section Diethyl 3-hydroxy-propynylphosphonate (8)
. A 1.6 M n-BuLi in hexanes (47.6 mL, 71.3 mmol) was added dropwise to a stirred solution of tetrahydro-2-(2-propynyloxy)-2H-pyran (7, 10 g, 71.3 mmol) in dry THF (100 mL) at -78 °C. After stirring for 30 min at the same temperature, a solution of diethylchlorophosphate (11.4 mL, 78.5 mmol) in dry THF (100 mL) was added dropwise, after which the mixture was stirred for another 30 min at -78 °C.
The reaction was quenched with saturated aqueous NH 4 Cl (100 mL) and the aqueous layer 
Diethyl 3-[N-benzyloxy,N-(2-nitrobenzenesulfonyl)amino]-propynylphosphonate (9).
To a stirred solution of alcohol 8 (6.58 g, 34.2 mmol), N-benzyloxy,N-(2-nitrobenzene)sulfonamide (11.5 g, 37.3 mmol) and PPh 3 (9.8 g, 37.3 mmol) in dry THF (180 mL) a solution of DEAD (6.91 mL 85%, 37.3 mmol) in dry THF (90 mL) was added over 1 h at rt. The mixture was stirred for 20 h at room temperature. 
Diethyl (E)-3-[N-(benzyloxy),N-(2-nitrobenzenesulfonyl)amino]-1-(tributylstannanyl)-
propenylphosphonate ( 3d,i-j, 4c,g-h, 5, 10g, 12b-h, 13b-d,h-j, 14h, 16 and 17), as well as full APT spectra of all new compounds. This material is available free of charge via Internet at http://pubs.acs.org.
